SEC Form 4 · accession 0001193125-26-301166
AN2 Therapeutics, Inc. · ANTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gilbert Lynn Marks
Director
Period of report
Jul 10, 2026
Accepted (ET)
Jul 10, 2026 · 7:41 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001880438
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 10, 2026 | A | 2,789 | $0.00 | A | 81,873 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.